argenx signs agreement to buy Forte Biosciences for $2.2bn
The transaction is expected to close in the third quarter of 2026.
28 July 2026
28 July 2026
The transaction is expected to close in the third quarter of 2026.
Through Labcorp OnDemand, the panel will be available from 3 August 2026.
In the ALXN1210-TMA-313 Phase III trial, Ultomiris did not achieve statistical significance for event-free survival.
Preliminary trial data showed a 100% en bloc resection and conversion-free rate.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.